MedTrace Logo

A Phase I Study of Adjuvant Chemotherapy With GC in Biliary Tract Cancer Undergoing Resection Without Major Hepatectomy

NCT01297998 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-11-17

No results posted yet for this study

Summary

To decide maximum tolerated dose and recommended dose of treatment using gemcitabine plus cisplatin combination therapy in patients with biliary tract cancer undergoing resection without major hepatectomy.

Conditions

  • Biliary Tract Cancer

Interventions

DRUG

gemcitabine , cisplatin

Dose of gemcitabine and cisplatin and treatment schedule

Sponsors & Collaborators

  • Kansai Hepatobiliary Oncology Group

    lead NETWORK

Principal Investigators

  • Tetsuo Ajiki, MD, PhD · Kobe University Graduate School of Medicine

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2012-12-31
Completion
2013-06-30

Countries

  • Japan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01297998 on ClinicalTrials.gov